A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)
A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC)
复制标题
DOI：
10.1007/s10637-005-4827-3
复制
发表时间：
2006-07-01
影响因子：
3.4
通讯作者：
Kraut, EH
中科院分区：
文献类型：
--
作者：
Bekaii-Saab, TS;Mortazavi, A;Kraut, EH
目的：II 期多中心研究调查了磺胺喹啉新型卤化衍生物氯喹喔啉磺酰胺 (CQS) 在转移性结直肠癌中的疗效和毒性。实验设计：符合条件的转移性或复发性结直肠癌患者接受 CQS 治疗，剂量为每周 1 小时 2000 mg/m(2)，持续 4 周，每 42 天一次。继续治疗直至出现意外的毒性或疾病进展。结果：共有 17 名患者参加了本研究。 94% 的入组患者之前接受过治疗。十六名患者的反应可进行评估，其中十五名患者显示出疾病进展的证据，一名患者的疾病长期稳定。一名患者患有无法评估的疾病。经过中期分析，该药物被认为无效，研究提前终止。最常见的不良事件是贫血。没有患者因毒性而停止治疗。结论：当转移性结直肠癌患者以每周 2000 mg/m(2) 的剂量连续 4 周、每 42 天服用 CQS 时，不会导致显着的肿瘤消退。
Purpose: Phase II multicenter study investigated the efficacy and toxicity of the novel halogenated derivative of sulfaquixonaline Chloroquinoxaline Sulfonamide (CQS) in metastatic colorectal cancer. Experimental design: Eligible patients with metastatic or recurrent colorectal cancer received CQS at a dose schedule of 2000 mg/m(2) over an hour weekly for 4 weeks every 42 days. Treatment was continued until unexpected toxicity or disease progression. Results: A total of seventeen patients were enrolled on this study. 94% of all patients enrolled had prior treatment. Sixteen patients were evaluable for response with fifteen patients showing evidence of disease progression and one patient with prolonged stable disease. One patient had non-evaluable disease. Following this interim analysis, the drug was considered ineffective and the study was terminated early. The most frequent adverse event was anemia. No patients discontinued the treatment because of toxicity. Conclusion: CQS, when given at a dose of 2000 mg/m(2) weekly for 4 weeks every 42 days to patients with metastatic colorectal cancer, does not result in significant tumor regression.